TSE:SVA Sernova Q1 2026 Earnings Report C$0.11 0.00 (0.00%) As of 02:23 PM Eastern ProfileEarnings History Sernova EPS ResultsActual EPSC$0.01Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ASernova Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASernova Announcement DetailsQuarterQ1 2026Date3/13/2026TimeAfter Market ClosesConference Call DateWednesday, March 18, 2026Conference Call Time12:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Sernova Earnings HeadlinesSERNOVA BIOTHERAPEUTICS INCJuly 28, 2026 | finanznachrichten.deSernova Biotherapeutics Inc.July 19, 2026 | barrons.comAfter KDA, PRE, and OCEAN—this is the one17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of. But the world's largest bank is already building on it. It has a deflationary burn mechanism tied directly to institutional usage.August 14 at 1:00 AM | Crypto 101 Media (Ad)Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total PancreatectomyJune 17, 2026 | markets.businessinsider.comStocks in play: Sernova Biotherapeutics Inc.June 17, 2026 | ca.finance.yahoo.comSernova Biotherapeutics, Inc.: Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total ...June 17, 2026 | finanznachrichten.deSee More Sernova Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Sernova? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sernova and other key companies, straight to your email. Email Address About SernovaSernova (TSE:SVA) Biotherapeutics is a clinical-stage company developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem-cell derived islet-like clusters in collaboration with Evotec to create bio-hybrid organs to treat T1D. A bio-hybrid organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This innovative approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on T1D and thyroid disorders.View Sernova ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Cerebras Sells Off After Earnings: Is This a Market Disconnection?Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?Sandisk’s Margins Look Like Software. Can They Last?SpaceX’s First Earnings Report Only Made Wall Street More DividedCAVA Earnings: The Easiest Comp of the Year Meets a Tough ValuationQuantum Leaps: Debt-Free as AI Storage Demand AcceleratesFranco-Nevada Earnings: Gold Is Rallying, But Does the Stock Even Care? Upcoming Earnings BHP Group (8/17/2026)Palo Alto Networks (8/17/2026)Home Depot (8/18/2026)Medtronic (8/18/2026)Keysight Technologies (8/18/2026)Lowe's Companies (8/19/2026)TJX Companies (8/19/2026)Target (8/19/2026)Analog Devices (8/19/2026)NetEase (8/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
